A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02247479 |
Recruitment Status
:
Completed
First Posted
: September 25, 2014
Last Update Posted
: April 18, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Geographic Atrophy | Drug: Lampalizumab Other: Sham | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 906 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration |
Actual Study Start Date : | September 18, 2014 |
Actual Primary Completion Date : | January 29, 2018 |
Actual Study Completion Date : | January 29, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Lampalizumab Once in Every Weeks (Q4W)
Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
|
Drug: Lampalizumab
Participants will receive 10 mg dose of lampalizumab administered intravitreally.
Other Name: RO5490249
|
Experimental: Lampalizumab Once in Every 6 Weeks (Q6W)
Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
|
Drug: Lampalizumab
Participants will receive 10 mg dose of lampalizumab administered intravitreally.
Other Name: RO5490249
|
Sham Comparator: Sham Comparator
Participants will receive sham comparator Q4W or Q6W for 96 weeks.
|
Other: Sham
A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
|
- Change from Baseline in GA Area, as Assessed by Fundus Autofluoresence (FAF) at Year 1 [ Time Frame: Baseline, Year 1 ]
- Change in Number of Scotomatous Points as Assessed by Mesopic Micrometry [ Time Frame: Baseline to Week 96 ]
- Change in Macular Sensitivity as Assessed by Mesopic Microperimetry [ Time Frame: Baseline to Week 96 ]
- Change in GA Area as Assessed by FAF [ Time Frame: Baseline to Week 96 ]
- Change in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart [ Time Frame: Baseline to Week 96 ]
- Change in BCVA Score as Assessed by ETDRS Chart Under Low Luminance Conditions [ Time Frame: Baseline to Week 96 ]
- Change in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts [ Time Frame: Baseline to Week 96 ]
- Change in Binocular Critical Print Size as Assessed by MNRead Charts or Radner Reading Charts [ Time Frame: Baseline to Week 96 ]
- Change in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score [ Time Frame: Baseline to Week 96 ]
- Change in NEI VFQ-25 Near Activity Subscale Score [ Time Frame: Baseline to Week 96 ]
- Change in NEI VFQ-25 Distance Activity Subscale Score [ Time Frame: Baseline to Week 96 ]
- Change in Functional Reading Independence (FRI) Index [ Time Frame: Baseline to Week 96 ]
- Percentage of Participants with Ocular Adverse Events [ Time Frame: Baseline up to the end of study (approximately 2 years) ]
- Percentage of Participants with Systemic (Non-ocular) Adverse Events [ Time Frame: Baseline up to the end of study (approximately 2 years) ]
- Percentage of Participants with Anti-Lampalizumab Antibodies [ Time Frame: Baseline up to the end of study (approximately 2 years) ]
- Prognostic Value of the Complement Factor I (CFI) Profile Biomarker Based on the Biomarker Status at Baseline and Change in the GA Area from Baseline as Measured by FAF at Year 1 [ Time Frame: Baseline, Year 1 ]
- Serum Lampalizumab Concentration [ Time Frame: Baseline to Week 96 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 50 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Well demarcated area(s) of GA secondary to AMD with no evidence of prior or active choroidal neovascularization (CNV) in both eyes
Exclusion Criteria:
Ocular Exclusion Criteria: Study Eye
- History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
- Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and proliferative diabetic retinopathy
- Previous intravitreal drug delivery (intravitreal corticosteroid injection, anti-angiogenic drugs, anti-complement agents, or device implantation) Ocular Exclusion Criteria: Both Eyes
- GA in either eye due to causes other than AMD
- Previous treatment with eculizumab, lampalizumab and/or fenretinide

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02247479

Study Director: | Clinical Trials | Hoffmann-La Roche |
Responsible Party: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT02247479 History of Changes |
Other Study ID Numbers: |
GX29176 2014-000107-27 ( EudraCT Number ) |
First Posted: | September 25, 2014 Key Record Dates |
Last Update Posted: | April 18, 2018 |
Last Verified: | April 2018 |
Studies a U.S. FDA-regulated Drug Product: | Yes | |
Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
Macular Degeneration Atrophy Geographic Atrophy Retinal Degeneration Retinal Diseases |
Eye Diseases Pathological Conditions, Anatomical Immunoglobulin Fab Fragments Immunologic Factors Physiological Effects of Drugs |